[Click here to subscribe to our NEW weekly newsletter!!]

Lilly posts 5 percent earnings gain in 2Q
Seattle Post Intelligencer, WA - Jul 24, 2003
... the Prozac franchise left off.". Cymbalta, a depression treatment,
could hit the market early next year. But its approval hinges ...

Lilly Posts 5 Percent Earnings Gain in 2Q
ABC News - Jul 24, 2003
... the Prozac franchise left off.". Cymbalta, a depression treatment,
could hit the market early next year. But its approval hinges ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Austin American Statesman, TX - Jul 24, 2003
... the Prozac franchise left off.''. Cymbalta, a depression treatment,
could hit the market early next year. But its approval hinges ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Atlanta Journal Constitution, GA - Jul 24, 2003
... the Prozac franchise left off.''. Cymbalta, a depression treatment,
could hit the market early next year. But its approval hinges ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Austin American Statesman, TX - Jul 24, 2003
... blockbuster anti-depressant Prozac. Cymbalta, a depression treatment,
could hit the market early next year. But its approval hinges ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Atlanta Journal Constitution, GA - Jul 24, 2003
... blockbuster anti-depressant Prozac. Cymbalta, a depression treatment,
could hit the market early next year. But its approval hinges ...

Lilly, Bristol Post Higher Profits; AstraZeneca Boosts Forecast
Bloomberg - Jul 24, 2003
... trying to fix quality-control flaws identified by regulators to gain US approval
of an injectable version of Zyprexa and a new depression drug called Cymbalta. ...

Schizophrenia treatment boosts Lilly sales
Financial Times (subscription), UK - Jul 24, 2003
... Lilly said it remains ready to launch four new products by the end
of next year, including a new depression treatment, Cymbalta. ...

Eli Lilly Tops Guidance
Smart Money - Jul 24, 2003
... In its early June announcement, Lilly said it expects to win crucial regulatory
approval of its antidepressant Cymbalta in the fourth quarter, despite ...

Lilly Net Up 5.1% on Phychosis, Osteoporosis Drug Sales
Quicken - Jul 24, 2003
... In its early June announcement, Lilly said it expects to win crucial regulatory
approval of its antidepressant Cymbalta in the fourth quarter, despite ...

Research is unraveling the strands of physical, psychological ...
Centre Daily Times, PA - Jul 20, 2003
... and the Indiana University School of Medicine, has been investigating duloxetine
for Eli Lilly and Co., which plans to market the drug under the name Cymbalta. ...

H Lundbeck downgraded to " neutral " - update
New Ratings - Jul 18, 2003
... However, the analyst observes that increasing growth through gains in
market share would mean combating Eli Lilly’s new drug, Cymbalta.

As Markets Rally, We Had Winners, Too
Quicken - Jul 9, 2003
... Lilly now expects to get FDA approval of a promising antidepressant, Cymbalta, later
this year, and the company recently said earnings for this quarter will be ...